Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. - Wikidata - awgldk - TriplyDB

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

http://www.wikidata.org/entity/Q34584174

about

Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.Arsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activation Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial Synergistic Apoptosis-Inducing Antileukemic Effects of Arsenic Trioxide and Mucuna macrocarpa Stem Extract in Human Leukemic Cells via a Reactive Oxygen Species-Dependent Mechanism.Phytochemicals in cancer prevention and therapy: truth or dare?Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.Arsenic-induced pancreatitis.The influence of modified pluronic F127 copolymers with higher phase transition temperature on arsenic trioxide-releasing properties and toxicity in a subcutaneous model of rats Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency Systematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor types.Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy.Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.Arsenic Trioxide and Icariin Show Synergistic Anti-leukemic Activity.Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.Acute arsenic trioxide ant bait ingestion by toddlers.Calcium homeostasis and endoplasmic reticulum stress are involved in Salvianolic acid B-offered protection against cardiac toxicity of arsenic trioxide.Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy.Effects of the combination of As2O3 and AZT on proliferation inhibition and apoptosis induction of hepatoma HepG2 cells following silencing of Egr-1.Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

P2860

Q24623800-BA91FC73-9322-429A-8B45-1EE3FCB4AE94 Q27852289-7B9DA298-3D4B-4443-B731-EB9F4F627AF3 Q28539034-34C742A5-5AAB-4E9D-8CC9-81B4F88796B4 Q28542497-900ACB5E-DEEC-41CA-941F-6F7AAC5112F5 Q33428982-6C4C8826-595E-4715-834B-AF9687337CDC Q33470967-EDF81BCA-1222-46BD-B53F-39699CF4EDFA Q33956059-894EA274-ADA7-4E2B-B110-4BF02611C39E Q35147292-12944D77-0CB8-4653-BC04-2FC8B1A23CCC Q35155749-4DBC442A-49B5-49E1-A914-C1E9D1A599A0 Q35586471-08414FFC-3916-4B2C-A0F4-3D3E34B5757D Q35800229-609253D0-C135-4495-B2FD-B3BC5BB4C928 Q35952893-70C60E7D-55E3-49A2-BFB0-68462024F503 Q35999080-772895BE-3AC8-40EB-A43E-B7372036FC76 Q36728942-ACE350C1-0736-4266-A982-6BEA79ADC9CD Q36866043-DFE1D526-334A-4B9F-95BB-7B9394087A64 Q36866821-881BF15E-893D-4359-B939-7C735112B93C Q37048013-558DABA4-9014-47B2-AF8E-E5B69413EDEC Q37480571-1E83BF05-6BE5-41AE-A5EE-6955757310ED Q38121136-E94B7030-8C89-4F2A-B976-0211526CD9B9 Q38185419-AC1FF10A-ABF2-4D2F-8C86-7386C9EFB384 Q38905593-84BD4FFE-A139-46DF-821C-35363B3F29D3 Q39281476-0FEC8B73-FD9E-47E6-8F46-F8C3402243F1 Q39537817-739CFE25-718F-43F3-BFE2-6C8F320CD490 Q40872029-A1147D9C-7489-4A80-B20C-EAC7A41B20EE Q40941767-2BB079DF-2EB4-4814-A917-C1702DE95D9F Q42749230-85BF6CF8-1FAF-4FA1-8436-332FE165FCCF Q44543518-84C94839-741F-4966-8748-DF2EBE905DCE Q47167565-E66A7B9B-645A-44EA-87AD-BCE044B77CBF Q48353831-71321C33-D979-4CAE-AFE0-A10AABD105CC Q48791883-D21C9090-0D73-4F26-95E3-F1EBFB3FFC3D Q49244147-5E73E7DE-39CB-405C-9513-E6B9CF268338 Q49511494-30F91777-225D-4E50-A757-DFE707C32E27 Q55313430-754272E9-166D-4556-99E9-B3F74FD77A3F Q57074270-8E4E2E9A-F93C-4254-A26B-4381F13BC1D7 Q58793896-A55F02F2-8EF5-485E-839A-44D6B1EA3E90

P2860

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

http://www.wikidata.org/entity/Q34584174

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@ast

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@en

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@nl

type

label

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@ast

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@en

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@nl

prefLabel

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@ast

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@en

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@nl

P1433

Q34584174-C2FBF050-7617-4852-A7E8-7C005E3B3765

P1476

Q34584174-D5CB1B86-9643-4FE2-A164-312E2C2879A8

P2093

Q34584174-1F3F0ED6-A9CF-4011-A10A-1F100EE10A04

Q34584174-728C31F9-08D4-4312-9066-87D7D05B9D04

Q34584174-8B40CFB3-E591-496E-B8BA-B576A537372E

Q34584174-9E53A719-6389-4B87-8ACE-601547C0F5F9

Q34584174-B5D23CAC-3B61-4A70-80FB-484357BB014A

Q34584174-BF4DE7A0-6740-405F-B7C5-D954C6629200

Q34584174-C8DF4458-3080-4C4C-BA45-C704BF60AA01

Q34584174-E4809F1A-124D-45AB-A82A-7D270C0018A9

Q34584174-EA3050AE-5D6C-45D7-A7FD-46F84D481E39

P2860

Q34584174-20F37DB9-5511-4AAF-8F1B-86C168310288

Q34584174-20F5E87B-CCB6-4C7D-9A5E-AE4B244E7C7A

Q34584174-2BFB3BF6-8A3A-45DA-94B0-7A31D58D3801

Q34584174-3A64FFEB-2E5E-4326-9A53-764EC4FC4C43

Q34584174-4E4D4642-B9FE-4604-B884-0CFC311CD65E

Q34584174-5BFE4A75-6002-41D3-B6D1-0B647AB52BFA

Q34584174-5C3AD689-A024-4B6E-AAB4-E431D9101838

Q34584174-634B87CD-9627-4A76-9E36-D1B08FD26D0B

Q34584174-676ABAB4-D6C8-4757-B0FE-26E7D732063B

Q34584174-6E7388C9-4AF4-4E22-8D22-9029FF1EDAED

P304

Q34584174-E74D11B1-945A-4059-87A6-D567933CFE43

P31

Q34584174-94AE04A2-8C15-4A3B-8A03-848889214CB6

P356

Q34584174-E52A0485-6753-4747-8418-B0785BC206C9

P407

Q34584174-B860C3EC-EEA1-485F-AF6B-D412032A04A6

P433

Q34584174-E1E63DEB-7DEF-44B9-9B89-1F6C95A752CB

P478

Q34584174-4F5BEEE6-1C88-45C1-A851-681CD0504B0F

P50

Q34584174-4E934011-4432-4ECB-A193-7EF537B825ED

Q34584174-D9734883-AC20-4DE3-A82A-7A4333149623

P577

Q34584174-89CFB08F-BEA3-4CAD-BA63-9DF5B6A4C56A

P5875

Q34584174-C2DA6E18-3048-4134-8BA7-B9517F4D3DDB

P698

Q34584174-D4680A43-C421-424F-B2E7-9F5EEE970E48

P921

Q34584174-24479160-F55B-46BD-A4DD-92110509883F

Q34584174-AA37D3CA-3633-46BD-8FEA-061A0DF462D0

Q34584174-B6E227B8-20AA-43A5-ADD6-C66504C0E108

P932

Q34584174-FB2AC9F8-8435-43EB-853E-89CA32721315

P356

BLOOD-2007-08-107839

P1433

P1476

Phase 1 trial and pharmacokine ...... elocytic leukemia or lymphoma.

@en

P2093

Anthony J Murgo

http://www.w3.org/2001/XMLSchema#string

Bassem I Razzouk

http://www.w3.org/2001/XMLSchema#string

Brigitte C Widemann

http://www.w3.org/2001/XMLSchema#string

Elizabeth Fox

http://www.w3.org/2001/XMLSchema#string

Gregory H Reaman

http://www.w3.org/2001/XMLSchema#string

Michelle O'Brien

http://www.w3.org/2001/XMLSchema#string

Peter C Adamson

http://www.w3.org/2001/XMLSchema#string

Shaun Xiao

http://www.w3.org/2001/XMLSchema#string

Wendy Goodspeed

http://www.w3.org/2001/XMLSchema#string

P2860

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

P304

566-573

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-08-107839

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5885711

http://www.w3.org/2001/XMLSchema#string

P698

17959855

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2200837

http://www.w3.org/2001/XMLSchema#string